

聯康集團  
Uni-Bio Science香江集團  
HEUNG KONG GROUP

## HeungKong Great Health Fund I injects HK\$120 million into Uni-Bio Science and becomes its strategic shareholder

\* \* \* \*

**Uni-Bio Science and HeungKong Group set up diverse strategic alliance for:**

- Expanding distribution network for pharmaceutical products
- Exploring setting up bio-pharmaceutical incubation centers
- Looking for international M&A projects

(Hong Kong, 18 July 2017) **Uni-Bio Science Group Limited** (“Uni-Bio Science”, “Uni-Bio” or the “Group”; HKEx code: 690) today announced that HeungKong Great Health Fund I, led by the famed Mainland China-based corporation HeungKong Group, has invested HK\$120 million in the Group and become its strategic shareholder. Uni-Bio Science and HeungKong Group also forged a strategic alliance, with the Group given access to the medical network of HeungKong Group to distribute its pharmaceutical products, and joint efforts will be made to evaluate the opportunities of setting up bio-pharmaceutical incubation centers and explore international M&A projects.

**Mr. Kingsley LEUNG, Chairman and Executive Director of Uni-Bio Science, said,** “*The cooperation with HeungKong Group marks an important milestone in the Group’s development. We are very encouraged by HeungKong Group’s decision to invest in Uni-Bio Science because that represents their firm recognition of our business directions and prospects. We believe combining HeungKong Group’s capital strength, medical network and investment banking experience with our professionalism and vision in the bio-pharmaceutical and related areas will see us make brilliant achievements and reap tremendous synergies, which can effectively enhance both parties’ leading presence in the health and pharmaceutical industries.*”

**Mr. Sam Lau, Deputy Chairman of HeungKong Group and Chairman of HeungKong Financial Group Limited, said,** “*Uni-Bio Science’s strengths in bio-pharmaceutics and bio-technology and its international perspective are what attracted HeungKong Group and the fund founded by Futec International Group to invest in and join hands with it to tap the international pharmaceutical industry. HeungKong Group is optimistic about Uni-Bio as a bio-pharmaceutical company with foresight, and its professional and technical expertise plus experience in drug development, registration and opening market access for its products are going to be helpful to Futec International Group in assessing potential investment projects effectively. The partnership between HeungKong Healthcare and Uni-Bio is also a marriage of complementary strengths that can help bring more advanced and higher quality drugs to China, as well as enable HeungKong Group to fulfill its solemn commitment of ‘giving back to society through business excellence’.*”

Partnering with quality companies to expand business has been a major corporate development strategy of Uni-Bio Science. In the past three years, the Group has built certain key partnerships conducive to product innovation, bringing in innovative pharmaceutical products and expanding its distribution channels, etc. This time, the Group will work with HeungKong Group on three major strategic areas, which are fostering expansion of the Group's distribution platform, enhancing innovation and pursuing overseas M&A, that fully agree with the Group's business development approach.

Reform of the healthcare system in Mainland China has begun, which will see follow-up consultation and dispensing of medicine at community health centers replacing visits to hospitals in chronic diseases management to reduce healthcare costs. To tap the business opportunities national policy brings, the Group is actively expanding its clinic network and distribution channels for some existing products and pipeline drugs for treating chronic diseases, such as diabetes and osteoporosis. Since it was set up in 2011 by HeungKong Group, HeungKong Healthcare has built a family health center chain that covers medical consultation service, and drug dispensaries and sanatorium operations, etc. And the Uni-Bio Science's aforementioned pharmaceutical products availed at HeungKong Group's family health centers means the community and patients with chronic diseases will have access to better daily or follow-up consultation and drug dispensary services. Moreover, HeungKong Healthcare will make use of Big Data in the future to establish an online health platform for offering products and services O2O. Thus, the cooperation between the two partners will not only enable the Group to perfect its distribution network for pharmaceutical products, but also see it enter the field of using Big Data applications in chronic diseases management.

The two partners will also look into opportunities of setting up bio-pharmaceutical incubation centers. With "external innovation" becoming a mainstream strategy in the global pharmaceutical industry, Uni-Bio Science intends to be the first in China to adopt the "external innovation" strategy, that is to work with external start-ups on new project incubation, to speed up new product development. Drawing from HeungKong Group's successful experience in building an A.I. incubation platform with Microsoft in Nansha, Guangzhou, and the Group's own R&D capability and pharmaceutical expertise, this innovative strategy stands well to be realized.

Furthermore, the Group will partner with Futec International Group, HeungKong Group's financial platform, to jointly explore and seize opportunities to acquire and merge with bio-pharmaceutical and bio-tech companies in the global market. Futec International Group boasts an experienced international team shrewd at capturing quality investment opportunities around the world. It plans to quickly establish foothold in the international innovative drug and pharmaceutical product markets. Capitalizing on Futec International Group's rich experience in investment banking and outstanding ability in searching for investment opportunities worldwide and the Group's solid track record in drug development, registration and opening market access for its products, more quality pharmaceutical products and advanced technologies will be introduced to China and patients in the country will have more innovative and reliable treatment choices.

- End -

Photo caption :

- 1) Mr. Kingsley LEUNG, Chairman and Executive Director of Uni-Bio Science (left on the front), and Mr. Sam Lau, Deputy Chairman of HeungKong Group and Chairman of HeungKong Financial Group Limited (right on the front), sign a strategic partnership agreement.



- 2) The Uni-Bio Science and HeungKong Group teams will work closely together to set up diverse strategic alliance.



(From left to right)

1	Financial Controller & Company Secretary of of Uni-Bio Science	Ms. Irene Yau
2	Independent Non-Executive Director of Uni-Bio Science	Mr. Paul Chow
3	Chairman and Executive Director of Uni-Bio Science	Mr. Kingsley Leung
4	Deputy Chairman of HeungKong Group and Chairman of HeungKong Financial Group Limited	Mr. Sam Lau
5	CEO of Futec International Holdings Limited	Mr. Tony Yau
6	Managing Director (Portfolio Management) of Futec International Holdings Limited	Mr. Curtis Liu

### **About Uni-Bio Science Group Limited (SEHK: 0690)**

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

### **About HeungKong Group**

HeungKong Group was established in 1990. After more than two decades' development, its businesses now cover several major areas including trade and logistics, property development, finance and investment, resources and energy and health, etc, being one of the companies selected as top 50 Private Enterprises in Mainland China. In 2011, HeungKong Group entered the high-end health and medical industry. The HeungKong healthcare segment focuses on elderly care and healthcare operations and provides supplementary light medical products and services. It has set up signature projects: HeungKong Wellness Valley, HeungKong Family Healthcare Center and Tianjin HeungKong Wellness Valley, to focus on the development of products for the HeungKong healthcare segment.

### **Media Enquiries:**

#### ***Strategic Financial Relations Limited***

Veron Ng	Phone: +852 2864 4831	Email: veron.ng@sprg.com.hk
Angelus Lau	Phone: +852 2864 4805	Email: angelus.lau@sprg.com.hk
Elaine Wang	Phone: +852 2864 4862	Email: elaine.wang@sprg.com.hk
	Fax: +852 2527 1196	

**WeChat ID: Unibio-IR**

心 創 造 新 醫 藥  
LEADING GENUINE INNOVATION

促進增長 國際視野 Accelerating Growth International Execution

